eicosapentaenoic acid ethyl ester has been researched along with Schizophrenia in 9 studies
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder." | 9.09 | A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. ( Boronow, J; Dickerson, F; Fenton, WS; Hibbeln, JR; Knable, M, 2001) |
| "This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder." | 5.09 | A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. ( Boronow, J; Dickerson, F; Fenton, WS; Hibbeln, JR; Knable, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qiao, Y | 1 |
| Mei, Y | 1 |
| Han, H | 1 |
| Liu, F | 1 |
| Yang, XM | 1 |
| Shao, Y | 1 |
| Xie, B | 1 |
| Long, B | 1 |
| Bentsen, H | 2 |
| Landrø, NI | 1 |
| Osnes, K | 1 |
| Refsum, H | 1 |
| Solberg, DK | 1 |
| Bøhmer, T | 1 |
| Veerman, SR | 1 |
| Schulte, PF | 1 |
| Begemann, MJ | 1 |
| de Haan, L | 1 |
| Pawełczyk, T | 2 |
| Grancow, M | 1 |
| Kotlicka-Antczak, M | 2 |
| Trafalska, E | 2 |
| Gębski, P | 1 |
| Szemraj, J | 1 |
| Żurner, N | 1 |
| Pawełczyk, A | 2 |
| Grancow-Grabka, M | 1 |
| Horrobin, DF | 1 |
| Berger, GE | 1 |
| Smesny, S | 1 |
| Amminger, GP | 1 |
| Fenton, WS | 1 |
| Dickerson, F | 1 |
| Boronow, J | 1 |
| Hibbeln, JR | 1 |
| Knable, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Omega-3 Fatty Acids in First-episode Schizophrenia - a Randomized Controlled Study of Efficacy and Relapse Prevention (OFFER). Rationale, Design, and Methods.[NCT02210962] | Phase 4 | 80 participants (Anticipated) | Interventional | 2011-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for eicosapentaenoic acid ethyl ester and Schizophrenia
| Article | Year |
|---|---|
Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Double-Blind | 2014 |
Bioactive lipids in schizophrenia.
Topics: Antipsychotic Agents; Arachidonic Acid; Brain; Clinical Trials as Topic; Drug Therapy, Combination; | 2006 |
5 trials available for eicosapentaenoic acid ethyl ester and Schizophrenia
| Article | Year |
|---|---|
Neurocognitive effects of an omega-3 fatty acid and vitamins E+C in schizophrenia: A randomised controlled trial.
Topics: Adult; Antipsychotic Agents; Ascorbic Acid; Attention; Eicosapentaenoic Acid; Executive Function; Fa | 2018 |
A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Ascorbic Acid; Double-Blind Method; Drug Therapy, Combinati | 2013 |
Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods.
Topics: Adolescent; Adult; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, U | 2015 |
A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Dietary Supplements; Double-Blind Method; Eico | 2016 |
A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Ei | 2001 |
2 other studies available for eicosapentaenoic acid ethyl ester and Schizophrenia
| Article | Year |
|---|---|
Effects of Omega-3 in the treatment of violent schizophrenia patients.
Topics: Adult; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Female; Humans; Male; | 2018 |
omega-3 Fatty acid for schizophrenia.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans | 2003 |